L iver disease, which is not uncommon in pregnancy, may be divided into four categories: liver diseases that are specific to pregnancy (intrahepatic cholestasis of pregnancy and acute fatty liver of pregnancy [AFLP] ), pregnancy disease with liver manifestations (hyperemesis gravidarum, preeclampsia, and hemolysis, elevated liver enzymes, and low platelet count syndrome), existing conditions that worsen during pregnancy (e.g., certain thrombotic diseases such as Budd-Chari but also hepatitis E), and intercurrent liver diseases independent of pregnancy (any liver disease, including liver tumors). These disorders constitute a significant health issue, and it has been estimated that more than 30,000 US women are admitted to the hospital during pregnancy each year because of liver disorders of pregnancy, another 21,000 because of gallbladder disease, and 8,000 each because of hepatitis C and biliary tract disease.
(1) Pregnancy-related liver disease is associated with substantial mortality. (2, 3) Although the guidelines of the American Association for the Study of Liver Diseases do not specifically comment on liver biopsy during pregnancy, (4) recent guidelines by the American College of Gastroenterology recommend that pregnant women with abnormal liver tests "should undergo standard workup as with any non-pregnant individual (strong recommendation, very low level of evidence)." (5) Despite this clear statement, there are few data on the safety of percutaneous liver biopsy during pregnancy. A PubMed search on February 28, 2017, yielded 269 hits for "liver biopsy AND pregnancy," including only nine women undergoing biopsy during pregnancy, (6) (7) (8) (9) (10) (11) out of which one pregnancy ended with stillbirth (10) and at least two with preterm birth. (6, 7) In addition, we have identified older reports of liver biopsy during pregnancy but without a systematic analysis of pregnancy outcome (12) and no attempt to calculate relative risks (RRs) for adverse pregnancy outcomes associated with liver biopsy. More commonly, the literature reports pregnancy-associated liver disease where biopsy is delayed until postpartum (13) (14) (15) or around delivery. (16) Given the lack of data on pregnancy outcome in relation to liver biopsy, we performed a nationwide population-based cohort study to examine the risk of adverse pregnancy outcomes in women undergoing liver biopsy compared with the general population.
Materials and Methods

REGISTRIES
All pregnancy data were obtained through the Swedish Medical Birth Registry (MBR). This registry was created in 1973 (data on smoking were added in 1983 and data on body mass index in 1992). For this reason, we restricted our study base to births occurring from 1992 to 2011. Through the MBR, we retrieved data on maternal age, parity, maternal country of birth, early pregnancy smoking status, and delivery year. Country of birth was divided into Nordic (Sweden, Denmark, Norway, Finland, and Iceland) and nonNordic countries. Data on smoking status, obtained at the first antenatal visit, were self-reported and divided into three categories: nonsmoking, light smoking (1-9 cigarettes/day), and heavy smoking (10 cigarettes/ day). A description of the study participants is given in Tables 1 and 2 .
Data on liver disease and liver biopsy were obtained from the Swedish Patient Registry. (17) This registry was established in 1964 and went nationwide in 1987. In the current study liver disease was equaled to hepatobiliary disease and defined in line with relevant International Classification of Diseases codes (Supporting Table S1 contains codes for liver disease from the Ninth and Tenth Revisions). Although we are unaware of any validation of liver diseases in the Swedish Patient Registry, for most nonliver diagnoses, the positive predictive values are about 85%-95%. (17) LIVER BIOPSY Liver biopsy performed during pregnancy was our exposure and defined per relevant procedure codes (5182, TJJ00, JJA2X). Furthermore, we used International Classification of Diseases and procedure codes to characterize women undergoing biopsy to identify cases with diagnosed complications, such as bleeding (Supporting Table S1 ). Liver transplantation was defined as having a procedure code: 5200, 5202, JJC00, JJC10, JJC20, JJC30, JJC40, JJC50, JJC60, or JJC96.
ARTICLE INFORMATION:
PREGNANCY OUTCOMES
Two main outcome measures were used: preterm birth and stillbirth. We hypothesized that liver biopsy might trigger preterm labor and stillbirth. Since mid-2008, stillbirth has been recorded in the MBR from 22 completed gestational weeks (before that, stillbirth was recorded from gestational week 28). Gestational age was defined through early second trimester ultrasound. When such data were missing, we used the first day of the last menstrual period. Routine ultrasound was offered to pregnant women in Sweden throughout the study period: 19/20 pregnant women will take advantage of this offer. Infants born before 37 completed gestational weeks were defined as preterm, with moderate preterm birth as 32-36 gestational weeks and very preterm birth as <32 completed gestational weeks.
Furthermore, we examined small for gestational age (SGA, here defined as a birth weight >2 standard deviations below the sex-specific mean for gestational age (18) according to Swedish ultrasound-based reference curves) and congenital malformations (using the same definition as in our recent report on endoscopy during pregnancy (19) ; see also Supporting Table S2 ). We also investigated the risk of induced labor, low birth weight (<2,500 g), cesarean section, Apgar score <7 at 5 minutes, and neonatal death (within 28 days after birth). Finally, we compared absolute birth weights and gestational age based on liver biopsy status.
This study was approved by the regional research ethics review board in Stockholm, Sweden (Dnr. 2008/ 1182-31/4). Because this was a strictly registry-based study and none of the study participants were contacted, informed consent was waivered by the review board. (20) 
STATISTICAL ANALYSES
We examined the risk of adverse pregnancy outcomes in women undergoing liver biopsy during pregnancy (Table 3) . Table 2 lists the categories used in our study.
To address the potential influence of underlying disease activity, we investigated the risk of adverse pregnancy outcome in women undergoing liver biopsy <1 year before or after pregnancy (n 5 384; Supporting Table S3 ). We then calculated RRs for adverse pregnancy in women having a biopsy during pregnancy (n 5 23) compared with those just before or after pregnancy (<1 year, n 5 384) (Table 4) .
Finally, to minimize the risk of intrafamilial confounding (and the risk that adverse pregnancy outcome and liver disease share genetic and environmental risk factors), we investigated pregnancy outcome in women with two or more pregnancies in which one was exposed to liver biopsy and the other was not (within the same mother).
For binary outcomes, we calculated RRs (with P values originating from Fisher's exact test). Because of the limited size of the data, we used the Clopper-Pearson method to calculate the confidence intervals for the probabilities of the binary outcomes. For continuous outcomes, we used the two-sample t test. To rule out that mother-specific and time constant omitted variable bias influenced our findings, we estimated the within-mother effect of liver biopsy using an exact version of McNemar's exact test for binary outcomes and fixed effects linear regression for continuous outcomes. The latter method could be seen as a generalization of the paired t test.
Only singleton births were used in the analyses. P < 0.05 (two-sided) was regarded as statistically significant. The analyses were conducted using Stata, version 13 (StataCorp, College Station, TX). 
Results
During the study period, there were 1,960,402 births in 1,135,983 unique women. In all, 23 pregnancies (and unique women) had been exposed to liver biopsy. Most of these (n 5 13) took place during the first month after conception (Supporting Table  S3 ).
Of the 23 women undergoing liver biopsy, 17 had a recorded liver diagnosis before pregnancy (as did 42,770 women without liver biopsy) ( Tables 1 and 2 ).
We had data on multiple pregnancies in 14 women exposed to liver biopsy in one of these pregnancies. Of the 23 women, 2 had undergone liver transplantation before pregnancy (Table 1) . Both of these women were biopsied in the first trimester.
None of the biopsied women had a diagnosis of bleeding in conjunction with the biopsy. The majority had undergone biopsy as inpatients, though few had stayed more than 1 day in the hospital (Table 1) . Ten women (44%) were biopsied in 2007 or later. Three of these 10 women had a diagnosis of cirrhosis already before pregnancy. The main underlying liver diseases in women undergoing liver biopsy were hepatitis C, autoimmune hepatitis, unspecified liver disease, and malignancy (Table 1) . Most women undergoing biopsy were born in the Nordic countries (79% of those undergoing biopsy compared with 83% of those who did not). The proportion of smokers was independent of liver biopsy status ( Table 2 ). The mean age among women with liver biopsy was 31 years versus 30 years among the general population controls (the mean age in women having a record of liver disease was 32 years). Additional characteristics of the participants are presented in Table 2 . 
MAIN RESULTS
There were no stillbirths in pregnancies exposed to liver biopsy (0%; 95% confidence interval [CI], 0%-14%), which can be compared with 0.3% stillbirths in unexposed pregnancies (95% CI, 0.3%-0.3%); 3/23 (13%; 95% CI, 3%-34%) exposed pregnancies were preterm compared with 5% (95% CI, 5%-5%) in unexposed pregnancies (Table 3) , which corresponded to an RR of 2.6 (95% CI, 0.9-7.5) ( Table 4) .
SGA was seen in 3/22 births (13%) compared with 3% in the general population controls and 3% of those with recorded liver disease. These differences were statistically significant compared with the general population (RR, 5.2; 95% CI, 1.8-14.8) and when we restricted our data to women with a record of liver disease (RR, 4.7; 95% CI, 1.3-17.2) (Table 4) . Similarly, we found an increased risk of low birth weight when using the general population as our reference but not when comparing with pregnancies to women with liver disease (Tables 3 and 4) . Whereas the risk of cesarean delivery showed a clear tendency toward significance compared with the general population controls (RR, 1.8; 95% CI, 0.9-3.6), there was no evidence of an increase when we restricted the controls to women with a liver disease diagnosis (RR, 0.9; 95% CI, 0.3-2.5).
With these exceptions, we found no statistically significantly increased risks of adverse pregnancy outcomes compared with the general population controls or the women with a diagnosis of liver disease (Tables 3 and  4) . None of the women undergoing liver biopsy gave birth to a child with a congenital malformation.
On average, women with liver biopsy gave birth about 10 days earlier than the general population controls and 6 days earlier than women with a diagnosis of recorded liver disease (Table 3 ). The mean birth weight difference was -367 g compared to the general population controls and -391 g using women with liver disease as controls.
Comparison With Controls Having Liver Biopsy <1 Year Before or After Pregnancy
Gestational age was similar in women with a biopsy during pregnancy as opposed to just before or after (P 5 0.121). Of 214 women with available data, 1 ended with stillbirth (0.47%) compared with 0/17 women with liver biopsy and liver disease. Low Apgar score was seen in 2.6%, neonatal death in 1.0%, and congenital malformation in 3.4% of pregnancies to women with liver biopsy near pregnancy; however, because none of these adverse outcomes occurred in women with a liver biopsy during pregnancy, no RRs were calculated. To rule out the potential influence of intrafamilial factors (genetic and environmental), we examined pregnancy outcomes within the same mother (i.e., comparing siblings of whom one had been exposed to liver biopsy and the other had not). For binary outcomes, this analysis was restricted to the control sibling most close in time to the index pregnancy. The analysis revealed no difference between biopsy-exposed pregnancies and sibling pregnancies for preterm birth, induction of labor, cesarean section, low Apgar score, neonatal death, or SGA. However, liver biopsy was associated with a 7-day shorter gestational age (95% CI, -12 to -2 days). The difference in absolute birth weight failed to reach statistical significance (-67 g; 95% CI, -249 to 1115 g).
Women With a Liver Biopsy <1 Year Before or After Pregnancy
Having a liver biopsy just before or after pregnancy was a risk factor for adverse pregnancy outcome (Supporting Table S3 ). Except for stillbirth, SGA, and congenital malformations, we found risk increases for all other outcomes, with a particularly high risk of neonatal death (RR, 5-6).
Discussion
This nationwide population-based study examined pregnancy outcomes in 23 pregnancies exposed to liver biopsy and compared these with more than 1.9 million unexposed pregnancies. None of the pregnancies exposed to liver biopsy ended with stillbirth; however, 3 (13%) were preterm and SGA, likely reflecting a true increase. Especially noteworthy is the finding that women having a liver biopsy before and after pregnancy were at increased risk of preterm birth (while the RR for SGA just failed to reach statistical significance). Overall, adverse pregnancy outcomes were rare, suggesting that liver biopsy need not be avoided because of pregnancy when there is a medical indication.
PREVIOUS LITERATURE
Research on pregnancy outcomes in women undergoing liver biopsy has largely been limited to case reports, (6) (7) (8) (9) (10) (11) often published many years ago, with some reporting adverse pregnancy outcomes. Further, much of the previous data from liver biopsies in pregnancy come from cases with AFLP because liver biopsy findings are one of the features of the Swansea criteria for AFLP, (21) although seldom performed. Still, existing guidelines and recently published reviews (5, 22) suggest that liver biopsies are generally safe and without references apart from AFLP studies but could often be deferred until after pregnancy or performed in conjunction with cesarean section. This cautiousness is likely due to worries that liver biopsies have an adverse effect on maternal or fetal health. Our data indicate that a substantial adverse effect is unlikely, and we found no increase in stillbirths, although we have few data on fetal loss in early pregnancy. Our study estimated RRs of adverse pregnancy effects. Except for SGA and low birth weight, RRs were neutral; however, we acknowledge our limited power and wide confidence intervals, indicating less precision. Of the 23 women with a liver biopsy during pregnancy, 2 had a record of a previous liver transplantation. The research of Westbrook et al. demonstrated that pregnancy following liver transplantation has a favorable outcome in the majority but still with severe maternal risks, the major (15% each) being preeclampsia/eclampsia and acute cellular rejection. (22) In that study, 16 out of 17 pregnant women diagnosed with acute cellular rejection underwent a liver biopsy during pregnancy or within 8 weeks of delivery, all with no complications.
STRENGTHS AND LIMITATIONS
Women undergoing liver biopsy during pregnancy are unlikely to be healthy, and effects on the fetus and pregnancy outcome may be due to both the liver biopsy procedure and the indication for biopsy. This is because liver disease, including AFLP, (21, 23) hepatitis C, (24) autoimmune hepatitis, (25) and liver cirrhosis, (26) may have a negative impact on pregnancy outcome. We approached this potential bias in various ways. First, we used several comparison groups. In the first comparison, we took advantage of the complete Swedish MBR with more than 1.9 million general population controls. This approach yields good statistical power and maximized our chances of detecting an increase in adverse pregnancy outcome. Second, we restricted our analyses to women with liver disease (in these analyses RRs decreased). We then investigated pregnancy outcomes that included women with a biopsy just before or after pregnancy as our reference group. Compared with this group of women, having a liver biopsy during pregnancy was not a risk factor for adverse pregnancy outcome. Finally, we had data on multiple pregnancies in 14 women exposed to liver biopsy in one of these pregnancies. Although it was difficult to estimate RRs for dichotomous outcomes (that often occur only in a low percentage of the pregnancies), we compared absolute birth weight and gestational age. We found that pregnancies exposed to liver biopsy, on average, ended 7 days earlier than nonexposed pregnancies. Otherwise, our analyses suggest that liver biopsy has no major influence on pregnancy outcome (binary outcomes did not differ). Among other strengths, we used independent registries to ascertain liver biopsy, liver disease, and pregnancy outcome. For instance, if data on liver disease had been collected retrospectively by the antenatal nurse collecting data on birth outcome, there would be a risk of bias (that women with mild liver disease but with poor pregnancy outcome would be classified as exposed, whereas those with a healthy child would be classified as unexposed, automatically inflating the RRs). We did not validate the liver disease diagnoses or the liver biopsy procedure specifically for this study. However, previous data suggest that the positive predictive value for most chronic diseases in the Swedish Patient Registry is approximately 85%-95%. (17) Our study has some weaknesses. Because we did not have data on type of sedation at liver biopsy, we cannot rule out that the positive association seen between liver biopsy and SGA and preterm birth in the general population analysis was influenced by sedation protocols and perioperative procedures. Furthermore, stillbirths in Sweden are only recorded from gestational week 22 (and until 2008 from week 28). Hence, we cannot draw conclusions on the risk of spontaneous abortion for liver biopsies taking place before gestational week 22. The main limitation, however, is the low number of liver biopsies together with the rare outcomes. This circumstance resulted in low statistical power and meant that we were unable to adjust our analyses for covariates. Even though the women undergoing liver biopsy were similar to the controls (Table 2) , adjustment for potential confounders may have influenced our results. In fact, the risks of adverse pregnancy outcomes in women having a liver biopsy in our study may well be an overestimate in that this group contained a higher proportion of smokers, women born outside the Nordic countries, and women with low education (these are all risk factors for adverse pregnancy outcome). Another limitation is that most women underwent liver biopsy during the first trimester. We lack information about indications for biopsy and whether women were aware of their pregnancy or not at the time of biopsy. Three patients had a record of known cirrhosis, and it is possible that they underwent early biopsy because later pregnancy in women with cirrhosis is often characterized by esophageal varices. It may also be that when there is a strong indication for liver biopsy in late pregnancy, delivery is induced and the biopsy performed postnatally rather than during pregnancy per se. The low number of endoscopies precluded us from any comparison of pregnancy outcome according to trimester, and our report offers limited data on the consequences of third-trimester liver biopsy. Also, Swedish registers do not record laboratory data, and hence, we were unable to measure liver disease severity using, e.g., serum bilirubin.
Finally, we carried out a large number of comparisons, and thus, we cannot rule out that some of our findings are due to chance (type 1 errors).
CLINICAL IMPLICATIONS
Our study adds evidence to the current guidelines suggesting that liver biopsy may be performed during pregnancy. The present findings are therefore reassuring to both pregnant women and physicians.
In conclusion, except for a moderately increased risk of preterm birth and SGA, this study found no association between liver biopsy during pregnancy and adverse pregnancy outcome. Potential excess risks should be weighed against the advantages of having a liver biopsy that may influence clinical management of the patient and indirectly fetal health. Our study adds evidence to the current guidelines suggesting that liver biopsy may be performed during pregnancy. Our findings are reassuring both to pregnant women and to physicians.
